| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 01/16/2002 | EP1171579A1 Human tumor necrosis factor receptor tr9 |
| 01/16/2002 | EP1171573A1 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171452A2 Pyrrolidincarbolylamino cyclic disulfides as vcam-vla4 antagonists |
| 01/16/2002 | EP1171442A1 Xanthine derivatives and analogs as cell signalling inhibitors |
| 01/16/2002 | EP1171441A1 Morphinoid compounds |
| 01/16/2002 | EP1171432A1 Adamantane derivatives |
| 01/16/2002 | EP1171425A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins |
| 01/16/2002 | EP1171419A1 Biphenyl derivatives as antagonists of the neurokinine-1 receptor |
| 01/16/2002 | EP1171159A2 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171131A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 01/16/2002 | EP1171125A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171122A1 Pyrrolidine modulators of chemokine receptor activity |
| 01/16/2002 | EP1171120A1 Methods for alleviating discomfort of a hot flash and compositions therefor |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1093374B1 Hypo-osmotic saline solutions, method for preparing same and medicines based on said solutions |
| 01/16/2002 | CN1331801A Kidney disease detection and treatment |
| 01/16/2002 | CN1331694A Antihistaminic spiro compounds |
| 01/16/2002 | CN1331691A Piperidines as CCR5 modulators |
| 01/16/2002 | CN1331688A Aminopyrazole derivatives |
| 01/16/2002 | CN1331682A Substituted 2-phenylbenzimidazoles, prodn. thereof and their use |
| 01/16/2002 | CN1331677A Pyrrolidine derivatives-CCR-3 receptor antagonists |
| 01/16/2002 | CN1331674A Sulfonamide hydroxamates |
| 01/16/2002 | CN1331597A Use of bisphosphonates for prevention and treatment of infectious processes |
| 01/16/2002 | CN1331591A Piperidines as CCR5 modulators |
| 01/16/2002 | CN1331590A Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating disease associated with increase of AT-1 or AT-2 receptors |
| 01/16/2002 | CN1331588A Use of 5HT2A and 5HT 2A-2C receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 01/16/2002 | CN1331581A Pharmaceutical aerosol compsn. contg. HFA227 and HFA 137 |
| 01/16/2002 | CN1077888C Benzopyrans and pharmaceutical compsn. contg. same |
| 01/16/2002 | CN1077791C Artificial snake bile and its mfg. method |
| 01/15/2002 | US6339107 Methods for treatment of Emphysema using 13-cis retinoic acid |
| 01/15/2002 | US6339094 2-acylaminopropanamines as tachykinin receptor antagonists |
| 01/15/2002 | US6339069 Administering formulation comprising pharmaceutically acceptable carrier; and, liposome comprising a bioactive agent and a lipid component, the lipid component comprising a peptide-lipid conjugate |
| 01/15/2002 | CA2094726C Non-chlorofluorocarbon aerosol formulation comprising a particulate medicament |
| 01/10/2002 | WO2002002744A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 01/10/2002 | WO2002002640A2 Antibodies to human mcp-1 |
| 01/10/2002 | WO2002002634A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/10/2002 | WO2002002633A2 Transporters and ion channels |
| 01/10/2002 | WO2002002603A2 Protein modification and maintenance molecules |
| 01/10/2002 | WO2002002587A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/10/2002 | WO2002002564A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | WO2002002556A2 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
| 01/10/2002 | WO2002002541A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002002525A2 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 01/10/2002 | WO2002002140A1 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 01/10/2002 | WO2002002134A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 01/10/2002 | WO2002002128A2 Oral compositions comprising antimicrobial agents |
| 01/10/2002 | WO2002002126A1 Medicaments containing dextrin for treating respiratory disorders such as cystic fibrosis |
| 01/10/2002 | WO2002002105A1 Therapeutic combinations of fatty acids |
| 01/10/2002 | WO2002002095A2 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin |
| 01/10/2002 | WO2002002090A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002001969A1 Vitamin k and essential fatty acids |
| 01/10/2002 | WO2001059071A3 Methods of preparing and using a viral vector library |
| 01/10/2002 | WO2001044455A3 Antisense oligonucleotides for the inhibition of expression of type i procollagen |
| 01/10/2002 | WO2001042192A3 Vla-4 integrin antagonists |
| 01/10/2002 | WO2001036425A3 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 01/10/2002 | WO2001034604A3 Adenosine receptor antagonists and methods of making and using the same |
| 01/10/2002 | WO2001028535A3 Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate |
| 01/10/2002 | WO2001000615A8 Respiratory syncytial virus replication inhibitors |
| 01/10/2002 | WO2000055332A3 Human regulators of intracellular phosphorylation |
| 01/10/2002 | US20020004580 Polypeptide; for use in the diagnosis and treatment of microorganismal infections; bactericides |
| 01/10/2002 | US20020004508 Novel carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines |
| 01/10/2002 | US20020004501 Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders |
| 01/10/2002 | US20020004494 Muscular disorders, gastrointestinal disorders, respiratory system disorders |
| 01/10/2002 | US20020004489 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 01/10/2002 | US20020004482 Treatment of acute lung injury and fibrosis with antagonists of avbeta6 |
| 01/10/2002 | US20020004046 Includes use of neutralizing antibody, high affinity antibodies, and viricide (ribavirin, amantadine, rimantadine, or a neuraminidase inhibitor); useful for controlling/treating respiratory syncytial virus in young children |
| 01/10/2002 | DE10030345A1 Hochkonzentrierte stabile Meloxicamlösungen Highly concentrated stable meloxicam |
| 01/10/2002 | DE10019714A1 Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines |
| 01/10/2002 | CA2415088A1 Aza-bridged-bicyclic amino acid derivatives as .alpha.4 integrin antagonists |
| 01/10/2002 | CA2414807A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414799A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414347A1 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 01/10/2002 | CA2413245A1 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412839A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 01/10/2002 | CA2412775A1 Antibodies to human mcp-1 |
| 01/10/2002 | CA2412620A1 Vitamin k and essential fatty acids |
| 01/10/2002 | CA2410945A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170594A2 Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2 |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169353A1 Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor |
| 01/09/2002 | EP1169346A1 48 human secreted proteins |
| 01/09/2002 | EP1169340A1 Lantibiotic |
| 01/09/2002 | EP1169338A2 Low-molecular inhibitors of complement proteases |
| 01/09/2002 | EP1169337A2 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction |
| 01/09/2002 | EP1169334A1 48 human secreted proteins |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169321A2 Purine derivatives having phosphodiesterase iv inhibition activity |
| 01/09/2002 | EP1169302A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169244A2 Metering valve |
| 01/09/2002 | EP1169082A1 Method of providing cosmetic/medical therapy |
| 01/09/2002 | EP1169046A1 Pulmonary delivery of protonated/acidified nucleic acids |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169029A1 Method of treating sleep apnoea |